CJC-1295 (No DAC) + Ipamorelin Blend — 10mg
$94.00
Research-grade CJC-1295 (No DAC) + Ipamorelin Blend, a dual-pathway growth hormone research complex combining Modified GRF (1-29) (5mg) and Ipamorelin (5mg). Studied for synergistic GHRH/GHS receptor co-activation and amplified pulsatile growth hormone release patterns. 10mg total lyophilized powder, 99%+ purity per component verified by Janoshik Analytical via HPLC and mass spectrometry.
-
For laboratory research use only.
-
Not for human or veterinary use.
-
Not intended for diagnosis, treatment, cure, or prevention of any disease.
-
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
CJC-1295 Ipamorelin Canada
CJC-1295 Ipamorelin Canada (No DAC) + Ipamorelin Blend, a dual-pathway growth hormone research complex combining Modified GRF (1-29) (5mg) and Ipamorelin (5mg). Studied for synergistic GHRH/GHS receptor co-activation and amplified pulsatile growth hormone release patterns. 10mg total lyophilized powder, 99%+ purity per component verified by Janoshik Analytical via HPLC and mass spectrometry.
-
For laboratory research use only.
-
Not for human or veterinary use.
-
Not intended for diagnosis, treatment, cure, or prevention of any disease.
-
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
This blend combines two of the most frequently co-administered peptides in growth hormone research: CJC-1295 (No DAC), a GHRH receptor agonist, and Ipamorelin, a selective ghrelin/GHS receptor agonist. The dual-pathway approach engages both the GHRH axis (upstream stimulation of GH synthesis and release) and the ghrelin axis (amplification of GH pulse amplitude) simultaneously, which published preclinical data suggests produces greater GH elevation than either compound alone. Durham Peptides also carries CJC-1295 (No DAC) and Ipamorelin individually for single-compound research.
BENEFITS/CJC-1295 Ipamorelin Canada
-
Dual-pathway GH research — GHRH + GHS receptor co-activation in a single vial
-
Synergistic signaling — published data suggests amplified GH pulse when both pathways are activated concurrently
-
Pulsatile profile — both components feature short half-lives preserving natural GH secretion patterns
-
Convenience — eliminates dual-vial reconstitution for combination protocols
-
Well-characterized components — both peptides have extensive published research individually
WHAT RESEARCHERS LOOK AT
-
Synergistic GH release: GHRH analog + GHS agonist combination vs. monotherapy
-
Pulsatile GH secretion patterns in pituitary cell models
-
IGF-1 downstream effects in combined GHRH/GHS activation
-
Comparative analysis vs. single-compound administration
-
Optimal ratios for dual-pathway GH research protocols
QUICK SPECS
-
Form: Lyophilized peptide blend
-
Net per vial: 10 mg total (CJC-1295 No DAC 5mg + Ipamorelin 5mg)
-
Purity: ≥99% per component (HPLC verified)
-
Identity: MS-verified for both components (per COA)
-
Storage: 2–8°C short-term, -20°C long-term, protect from light and moisture
-
Reconstitution: Use bacteriostatic water (sold separately)
IDENTITY BASICS
-
Components: CJC-1295 No DAC (CAS 446036-97-1) + Ipamorelin (CAS 170851-70-4)
-
CJC-1295 No DAC: 30-amino-acid GHRH analog, 3367.9 g/mol
-
Ipamorelin: Pentapeptide GHS receptor agonist, 711.85 g/mol
-
Blend total: 10 mg per vial (5mg + 5mg, 1:1 ratio)
Be the first to review “CJC-1295 (No DAC) + Ipamorelin Blend — 10mg”
Related products
Retatrutide Canada
Retatrutide Canada
Retatrutide Canada
Retatrutide Canada
Retatrutide Canada
Retatrutide Canada
Retatrutide Canada
Retatrutide Canada
Reviews
There are no reviews yet.